Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis.

ABSTRACT:

Background

To evaluate the comparative efficacy and safety of baricitinib with different dosages in patients with rheumatoid arthritis (RA).

Methods

PubMed, Embase, and the Cochrane Library were retrieved by computer to gather randomized controlled trials (RCTs) of baricitinib for RA from their beginning to September 2021. After 2 researchers independently screened the literature and extracted the data, the risk of bias of included RCTs was assessed, and Bayesian network meta-analysis was performed by GeMTC0.14.3 and Stata15.1 software.

Results

Ten publications reporting 9 RCTs were included, with 4129 patients randomized to receive 1 of the 7 interventions. Seven interventions were baricitinib 1 mg + conventional disease-modifying antirheumatic drugs (cDMARD), barici

SUBMITTER: Haikun W 

PROVIDER: S-EPMC9509125 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature